Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Other Working Capital Changes (2016 - 2025)

Integra Lifesciences Holdings' Other Working Capital Changes history spans 17 years, with the latest figure at $685000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 101.99% year-over-year to $685000.0; the TTM value through Dec 2025 reached $3.4 million, up 3755.91%, while the annual FY2025 figure was $3.4 million, 3755.91% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $685000.0 at Integra Lifesciences Holdings, up from $371000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $25.0 million in Q2 2023 and bottomed at -$34.5 million in Q4 2024.
  • The 5-year median for Other Working Capital Changes is $853000.0 (2023), against an average of -$257450.0.
  • The largest annual shift saw Other Working Capital Changes soared 290.03% in 2023 before it plummeted 3478.45% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$11.7 million in 2021, then increased by 4.56% to -$11.1 million in 2022, then skyrocketed by 109.17% to $1.0 million in 2023, then tumbled by 3478.45% to -$34.5 million in 2024, then skyrocketed by 101.99% to $685000.0 in 2025.
  • Per Business Quant, the three most recent readings for IART's Other Working Capital Changes are $685000.0 (Q4 2025), $371000.0 (Q3 2025), and $2.1 million (Q2 2025).